← Back to Clinical Trials
Recruiting NCT03672760

NCT03672760 Inspiratory Muscle Training X CardioBreath App Effects On Vagal Modulation And Pulse Wave Velocity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03672760
Status Recruiting
Phase
Sponsor Instituto de Cardiologia do Rio Grande do Sul
Condition Postmenopausal Disorder
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2023-09-01
Primary Completion 2024-11-30

Eligibility & Interventions

Sex Female only
Min Age 45 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
CardioBreathAppIMT PowerBreathIMT PowerBreath Placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2023-09-01 with a primary completion date of 2024-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Existing data points to relevant beneficial effects of respiratory exercises on cardiovascular health, with special regards to decreases on arterial pressure and improves on autonomic and vascular profiles, though mechanistics of such results have not yet been cleared. Among the available ways to perform respiratory exercises, there is the highly recommended Inspiratory Muscle Training (IMT) and slow breathing exercises like Yoga pranayamas. Lately, the development of new technologies has allowed the use of Apps to perform respiratory exercises. This study will be take the just developed CardioBreath®App to validate it as a tool to perform respiratory exercises. Therefore, it will be compared to IMT on cardiac vagal modulation and pulse wave velocity on normotensive post menopause women.

Eligibility Criteria

Inclusion Criteria: * Follicle Stimulating Hormone (FSH)\>35mui/ml * minimum 12 months amenorrhea * sedentary life style (less than 150 minutes per week of exercise) Exclusion Criteria: * Hypertension * Diabetes * Obesity * Use of Betablockers * recent cardiovascular events or surgery * renal alterations * respiratory and/or motor pathologies * smoking * BMI\>29,9

Contact & Investigator

Central Contact

Cláudia Fetter, MSc

✉ profclaudiafetter@gmail.com

📞 +5551984516888

Frequently Asked Questions

Who can join the NCT03672760 clinical trial?

This trial is open to female participants only, aged 45 Years or older, up to 65 Years, studying Postmenopausal Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03672760 currently recruiting?

Yes, NCT03672760 is actively recruiting participants. Contact the research team at profclaudiafetter@gmail.com for enrollment information.

Where is the NCT03672760 trial being conducted?

This trial is being conducted at Porto Alegre, Brazil.

Who is sponsoring the NCT03672760 clinical trial?

NCT03672760 is sponsored by Instituto de Cardiologia do Rio Grande do Sul. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology